Last reviewed · How we verify
intra-operative 5-FU chemotherapy
At a glance
| Generic name | intra-operative 5-FU chemotherapy |
|---|---|
| Also known as | intra-operative 5-FU chemotherapy for colorectal cancer |
| Sponsor | Sun Yat-sen University |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer (PHASE3)
- Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer (PHASE2)
- Treatment of Primary Peritoneal Carcinosis of Digestive Origin Using Cytoreductive Surgery and Hyperthermic Intraoperative Peritoneal Chemotherapy With Mitomycin C and Irinotecan (PHASE1, PHASE2)
- Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer (PHASE3)
- Second and Third Look Laparoscopy in pT4 Colon Cancer Patients for Early Detection of Peritoneal Metastases (PHASE3)
- Salvage Chemotherapy Versus Total Mesorectal Resection for Local Resection Rectal Cancer Patients (NA)
- Evaluation of Surgery Versus Primary Chemotherapy in Resectable Signet Ring Cell Gastric Adenocarcinoma (NA)
- Induction Chemotherapy for Locally Recurrent Rectal Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- intra-operative 5-FU chemotherapy CI brief — competitive landscape report
- intra-operative 5-FU chemotherapy updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI